Fresh analysis indicates that patients who come off popular weight-loss injections like Mounjaro or Wegovy may regain lost weight far faster than those who halt conventional diet and exercise regimens.
Research printed in a leading health publication points out that while overweight individuals often shed about a fifth of their total mass while using the jabs, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"Users buying such drugs must be informed of the danger of rapid weight regain when the therapy ends," warns expert Dr. Susan Jebb.
Such speed of recovery implies a return to original weight within about 18 months.
Analyzing Therapies
The research, which looked at 37 of studies involving thousands of participants, contrasted the results of these new drugs with other pills.
Researchers note that individuals who lose weight through dieting generally have a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Regain
Nutrition scientists suggest the way of the jabs is key to understanding the accelerated regain.
The injections copy a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the system to produce less of its endogenous hormone, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making excessive eating much more probable."
An Ongoing Disease?
Health authorities suggest the injections for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, due to the likelihood of weight regain, the treatment might need to be ongoing.
This view is echoed by drug manufacturers, who state that the results "emphasize the chronic character of obesity," akin to managing conditions like high blood pressure.
Patient Testimonies
Users who have stopped the jabs explain a sudden return of hunger.
"I experienced a trigger activating and you become ravenous," described an individual.
The struggle is worsened if patients have not adopted permanent dietary or behavioural changes during therapy.
Widespread Adoption
Figures suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is greater among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians stress that while these medications are effective tools for shedding pounds, they are not a permanent solution and long-term success likely depends on ongoing lifestyle management.
